(1) | Assessing equivalence in clinical outcome using the MYMOP2 score. |
(2) | Examining clinical outcome at 6 weeks using the SF-36 PCS |
(3) | Comparing the proportion of patients who 'respond to treatment' in each arm, in line with the Outcomes Measures in Rheumatology Clinical Trials- Osteoarthritis Research Society International (OMERACT-OARSI) recommendations [30], using the SF-36 physical function and bodily pain scales and the global improvement score |
(4) | Repeating the primary analysis adjusting also for any variables exhibiting marked imbalance at baseline to check that this does not influence the findings |
(5) | Analyses as above for secondary outcomes (where p-values will be adjusted to account for multiple testing) |
(6) | Investigating the effectiveness and cost-effectiveness of PhysioDirect for patients of different age-groups, or with different presenting problems |
(7) | Investigating the effectiveness and cost-effectiveness of PhysioDirect in each of the four PCTs, in exploratory sub-group analyses |
(8) | Investigation of process measures such as physiotherapy consultation rates, physiotherapy 'did-not-attend' rates and consultation rates with other health care services in the NHS and private sectors |